These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26339644)

  • 1. B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia.
    Rihacek M; Bienertova-Vasku J; Valik D; Sterba J; Pilatova K; Zdrazilova-Dubska L
    Biomed Res Int; 2015; 2015():792187. PubMed ID: 26339644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB; Morand EF; Mackay F
    Immunol Cell Biol; 2012 Mar; 90(3):293-303. PubMed ID: 22231653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating levels of B-cell activating factor in paediatric patients with malignancy with or without cancer-related cachexia.
    Bienertova-Vasku J; Lungova A; Bienert P; Zlamal F; Tomandl J; Tomandlova M; Splichal Z; Sterba J
    Klin Onkol; 2012; 25 Suppl 2():2S58-63. PubMed ID: 23581018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B-cell activating factor targeted therapy and lupus.
    Boneparth A; Davidson A
    Arthritis Res Ther; 2012; 14 Suppl 4(Suppl 4):S2. PubMed ID: 23281926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
    Shin W; Lee HT; Lim H; Lee SH; Son JY; Lee JU; Yoo KY; Ryu SE; Rhie J; Lee JY; Heo YS
    Nat Commun; 2018 Mar; 9(1):1200. PubMed ID: 29572471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
    Stohl W
    Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
    Samy E; Wax S; Huard B; Hess H; Schneider P
    Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
    Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
    J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
    Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
    Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rationale for BAFF inhibition in systemic lupus erythematosus.
    Davidson A
    Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?
    Hengeveld PJ; Kersten MJ
    Blood Cancer J; 2015 Feb; 5(2):e282. PubMed ID: 25723853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.
    Kowalczyk-Quintas C; Chevalley D; Willen L; Jandus C; Vigolo M; Schneider P
    Front Immunol; 2018; 9():2698. PubMed ID: 30524439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis.
    Vallerskog T; Heimbürger M; Gunnarsson I; Zhou W; Wahren-Herlenius M; Trollmo C; Malmström V
    Arthritis Res Ther; 2006; 8(6):R167. PubMed ID: 17092341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAFF and selection of autoreactive B cells.
    Liu Z; Davidson A
    Trends Immunol; 2011 Aug; 32(8):388-94. PubMed ID: 21752714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
    Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
    Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).
    Stohl W
    Expert Rev Clin Immunol; 2017 Jun; 13(6):623-633. PubMed ID: 28164726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
    Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
    Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.